LIPO has a new catalystReuters: "Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research"
Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth
No FDA-approved therapy currently exists for OLP
Patient registry and OLP stu